Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8517244 | 0.75 | POLB (0.41) | POLBCYP1A2KMT2A | |
| SCHEMBL8372062 | 0.75 | POLB (0.41) | POLBCYP1A2KMT2A | |
| SCHEMBL27128856 | 0.75 | POLB (0.41) | POLBCYP1A2KMT2A | |
| SCHEMBL8517246 | 0.75 | POLB (0.41) | POLBCYP1A2KMT2A | |
| SCHEMBL8372064 | 0.75 | POLB (0.41) | POLBCYP1A2KMT2A | |
| SCHEMBL4193718 | 0.74 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL7103874 | 0.74 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL4192717 | 0.74 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL10691070 | 0.73 | ALDH1A1 (0.37) | KDM4EKDM4CCCR5CYP1A2MEN1 | |
| SCHEMBL27032120 | 0.73 | KDM4C (0.38) | POLBKDM4CCYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176710-A1 | C1-C6-epothilone fragments and process for the production of C1-C6-fragments of epothilones and derivatives thereof | SCHERING AG (DE) | 2003-09-18 | — | — | US | disclosed |
| WO-2003053949-A1 | C1-C6 FRAGMENTS OF EPOTHILONES AND METHOD FOR PRODUCING SUCH FRAGMENTS AND THE DERIVATIVES THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176710-A1 | C1-C6-epothilone fragments and process for the production of C1-C6-fragments of epothilones and derivatives thereof | CYC1, DHPS, C1S | POLB 3438/4885KDM4E 4113/4885KDM4C 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.